top of page

Press Release | EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026

  • Jun 30
  • 1 min read

EIT Pharma, led by Dr. Leen Kawas, presented new analyses from the phase 3 D-LIVR trial at EASL Congress 2026 in Barcelona, adding to the evidence base for lonafarnib, currently the only oral therapy in late-stage development for chronic hepatitis D. The full press release covers what was presented, what the data shows, and where the program goes from here.



 
 
 

Comments

bottom of page